– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD reinforces potential as a sustained six-month maintenance therapy – – Phase 2 trial of DURAVYU in diabetic macular edema (DME) fully enrolled – – EyePoint to webcast its R&D Day event today at 8 ...

An overview of the science behind DURAVYU™ (vorolanib intravitreal insert), formerly known as EYP1901, an investigational sustained-release therapy with the potential to alter the treatment paradigm for patients suffering from VEGF-mediated retinal diseases A review of the positive Phase 2 DAVIO 2 trial results in wet AMD, including 12-month topline data An update on the pivotal non-inferiority Phase 3 trial plans for DURAVYU™ in wet AMD A KOL roundtable discussion with Drs. Regillo and Modi moderated by Ey ...

An overview of the science behind DURAVYU™ (vorolanib intravitreal insert), formerly known as EYP1901, an investigational sustained-release therapy with the potential to alter the treatment paradigm for patients suffering from VEGF-mediated retinal diseases A review of the positive Phase 2 DAVIO 2 trial results in wet AMD, including 12-month topline data An update on the pivotal non-inferiority Phase 3 trial plans for DURAVYU™ in wet AMD A KOL roundtable discussion with Drs. Regillo and Modi moderated by Ey ...

WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisd ...

– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to demonstrate favorable safety and tolerability profile with no drug-related serious adverse events – – Conference call to discuss the results to be held at 8:00 a.m. ET – WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with se ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Conference Call March 7, 2024 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Tessa Romero - JPMorgan Tyler Van Buren - TD Cowen Yatin Suneja - Guggenheim Jennifer Kim - Cantor Fitzgerald Graig Suvannavejh - Mizuho Securities Colleen Kusy - Baird Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright Operator Good morning. My name is Kevi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...

EyePoint Pharmaceuticals (EYPT) reported $14.03 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 33.2%. EPS of -$0.33 for the same period compares to -$0.61 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $8.71 million, representing a surprise of +61.00%. The company delivered an EPS surprise of +45.00%, with the consensus EPS estimate being -$0.60.While investors scrutinize revenue and earnings changes year-over-year and how they ...

– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H 2024 – – Dosed first patient in Phase 2 VERONA clinical trial of EYP-1901 in DME; topline data expected in 1Q 2025 – – Phase 2 PAVIA clinical trial topline data of EYP-1901 in moderately severe-to-severe NPDR anticipated in 2Q 2024 – – Announced appointment of Ramiro Ribeiro, M.D., Ph.D. as Chi ...